MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hep.0000000000001605

Медицинская библиотека · Hepatology (Baltimore, Md.) · 2025

GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.

Jiang Yifan, Li Yu, Wu Tong, Cao Linping, Xu Guangming, Liu Jiwei, Hua Chenguang, Ding Chaofeng, Yang Beng, Tong Rongliang, Chen Diyu, Wu Jian

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Messenger RNA (mRNA) vaccine is a promising approach for cancer therapy. However, the development of mRNA cancer vaccines encounters several challenges, including mRNA instability, inefficient delivery systems, and potential biosafety concerns. Addressing these issues requires optimizing mRNA design, developing novel delivery vectors, and enhancing immune responses. We aimed to develop a circular RNA (circRNA)-based cancer vaccine targeting tumor-associated antigen Glypican-3 (GPC3), a promising target in hepatocellular carcinoma (HCC), to improve antigen stability and anti-tumor immune responses.

APPROACH AND

RESULTS

We designed a circRNA-based vaccine encoding GPC3 for HCC and evaluated the therapeutic efficacy and safety of the circGPC3 vaccine. The circGPC3 vaccine demonstrated sustained antigen production, overcoming the inherent limitations of traditional mRNA vaccines and resulting in more potent and durable anti-tumor immune responses. In addition, we incorporated a Toll-like receptor 4 (TLR4) agonist as an adjuvant to further enhance immune responses. CircGPC3 vaccine plus TLR4 agonist effectively suppressed tumor progression in HCC. We employed multiplex immunofluorescence, single-cell sequencing, spatial transcriptomics, and mass cytometry to characterize the tumor microenvironment (TME) in mice following combination therapy and to elucidate the mechanism. Mechanistically, the circGPC3 vaccine significantly enhanced immunoproteasome-mediated antigen presentation and strengthened the interaction between cDC1 and CD8 + T cells through the MHC-I pathway, therefore facilitating a more effective initiation of adaptive immune responses and reprogramming TME.

CONCLUSIONS

The circGPC3 cancer vaccine demonstrated superior efficacy compared with the mRNA cancer vaccine. When further combined with a TLR4 agonist, it disrupted immune tolerance in HCC, offering a promising translational treatment strategy for HCC.

Для цитирования: Jiang Yifan, Li Yu, Wu Tong, Cao Linping, Xu Guangming, Liu Jiwei, Hua Chenguang, Ding Chaofeng, Yang Beng, Tong Rongliang, Chen Diyu, Wu Jian. GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.. Hepatology (Baltimore, Md.). 2025. DOI: 10.1097/hep.0000000000001605.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.